RespireRx Pharmaceuticals Inc (RSPI)

[LTListener]

I have seen where many pharma deals get structured as such. Cash up front and then boatloads more cash as the continued development efforts hit further milestones.

With the lack of 10-k, and complete silence from the company, it feels like "maybe" some negotiations are on the table currently. That is all pure speculation, but as discussed here, OSA preclincals and the NIH tier 3 preclinicals should be advancing to some stage to now know if ready to launch into human clinical trials.

I highly doubt too that BP would want to deal with OTC shenanagins, so possibly/hopefully any type of deal would also include plans to trade on a higher exchange. This alone would significantly help support the other drug development programs. Either way, when some equity is valued at a mere 1 million and has pharma asset appreciation potential into the 100's of millions with market potential into the billions, there is some upside in the risk v reward equation!